Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Esperion Theraptc (NQ: ESPR ) 1.780 -0.120 (-6.32%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Esperion Theraptc < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 12, 2024 ESPR stock results show that Esperion Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket August 12, 2024 Via Benzinga Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update August 12, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) August 07, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion to Report Second Quarter 2024 Financial Results on August 12 July 25, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion to Participate in Upcoming BTIG Biotech Conference July 24, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries July 16, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility June 28, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Wall Street's Top 10 Stock Calls This Week - Saturday, June 22 June 22, 2024 What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024. Via Talk Markets Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session June 20, 2024 Via Benzinga Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday June 20, 2024 Via Benzinga Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget June 13, 2024 Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. Via InvestorPlace 3 Penny Stocks to Buy if You Want to Spend Less and Earn More June 11, 2024 These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential. Via InvestorPlace Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 10, 2024 Via Benzinga Argan Reports Strong Earnings, Joins Geron, Planet Labs PBC And Other Big Stocks Moving Higher On Friday June 07, 2024 Via Benzinga Esperion to Participate in Upcoming June Investor Conferences May 23, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk May 22, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study May 20, 2024 Esperion Therapeutics and Otsuka Pharmaceutical report Phase 3 trial results for bempedoic acid in Japan, achieving significant LDL-C reduction in hypercholesterolemia patients. With no serious adverse... Via Benzinga Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia May 20, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® May 14, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) May 10, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS May 08, 2024 Via AB Newswire ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 ESPR stock results show that Esperion Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars May 07, 2024 Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA approved expanded labels for NEXLETOL & NEXLIZET. Fiscal year 2024... Via Benzinga Exposures Product Safety Why Is AgriFORCE Growing (AGRI) Stock Down 31% Today? May 07, 2024 AgriFORCE Growing stock is falling hard on Tuesday after the company announced an offering for AGRI shares from stockholders. Via InvestorPlace Why Is GreenPower Motor (GP) Stock Down 36% Today? May 07, 2024 GreenPower Motor stock is down on Tuesday after the EV company priced a public offering for 1.5 million shares of GP stock. Via InvestorPlace Why Is Esperion Therapeutics (ESPR) Stock Up 13% Today? May 07, 2024 Esperion Therapeutics stock is up on Tuesday with heavy trading of ESPR shares after the company beat EPS and revenue estimates in Q1. Via InvestorPlace 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 07, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday May 07, 2024 It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Tuesday! Via InvestorPlace Esperion Reports First Quarter 2024 Financial Results May 07, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.